DORIBAX
LOE ApproachingNDAINTRAVENOUSINJECTABLE
Approved
Oct 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORIBAX is an intravenous injectable antibiotic approved in 2007 by Shionogi for treating bacterial infections. The drug's specific mechanism of action and therapeutic indications are not fully characterized in available data, but it represents a mature injectable anti-infective option. As an IV formulation, it is primarily used in acute care and hospital settings.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), likely requiring cost and market access strategy focus rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
37 linked positions indicate active hiring around DORIBAX, primarily in Commercial and Quality Assurance functions. The role distribution suggests focus on cost management, market access strategy, and regulatory/quality sustainability as the product enters its LOE phase rather than growth-focused expansion.
LongDirector
Worked on DORIBAX at Shionogi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.